Serum p‐tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic <scp>REM</scp> Sleep Behavior Disorder
Serum p-tau217, but not NfL, is a useful biomarker of cognitive impairment in iRBD that could be integrated into a multimodal prognostic indicator when stratifying risk of phenoconversion. ANN NEUROL 2026;99:912-921.
Authors
- Akhila K. Sahoo (ORCID: https://orcid.org/0000-0001-5570-4759)
- Wolfgang H. Oertel (ORCID: https://orcid.org/0000-0002-7582-8166)
- Shijun Yan (ORCID: https://orcid.org/0009-0007-4933-4238)
- George K. Tofaris (ORCID: https://orcid.org/0000-0002-9252-5933)
- Tanja Zerenner (ORCID: https://orcid.org/0000-0002-4672-5619)
- Michael Sommerauer (ORCID: https://orcid.org/0000-0001-5723-9766)
- Kenneth Marek (ORCID: https://orcid.org/0000-0002-4197-5627)
Institutions
- University of Bonn (DE)
- Philipps University of Marburg (DE)
- University of Cologne (DE)
- German Center for Neurodegenerative Diseases (DE)
- University of Bristol (GB)
- University of Oxford (GB)
- Institute for Neurodegenerative Disorders (US)
- University Hospital Cologne (DE)
Publication Details
- Journal
- Annals of Neurology
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1002/ana.78109
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- UK Research and Innovation
- ParkinsonFonds Deutschland
- National Institute for Health and Care Research
- Parkinson's UK
- Else Kröner-Fresenius-Stiftung
- Universität zu Köln
- Stichting ParkinsonFonds
- Medical Research Council
- NIHR Oxford Biomedical Research Centre